devimistat + gemcitabine

**Devimistat + gemcitabine** is an investigational combination therapy primarily studied in advanced biliary tract cancer. **Devimistat** (CPI-613) is a novel lipoate analog that selectively inhibits key mitochondrial enzymes—namely pyruvate dehydrogenase and α-ketoglutarate dehydrogenase—within the tricarboxylic acid (TCA) cycle of cancer cells, disrupting cellular energy metabolism and potentially augmenting the cytotoxicity of standard chemotherapy agents like gemcitabine. **Gemcitabine** is a nucleoside analog that interferes with DNA synthesis, exerting cytotoxic effects as an antimetabolite. Preclinical studies have demonstrated synergistic antitumor activity for the devimistat + gemcitabine (often with additional cisplatin) regimen, and clinical trials have shown encouraging efficacy and safety profiles. The combination is administered intravenously and has shown acceptable toxicity and promising progression-free survival in multiple phase 1b/2 studies focused on untreated advanced biliary tract cancers[1][2][3][5][7].

Other names

devimistat + gemcitabine